Minerva Neurosciences (NERV) Competitors $1.64 -0.01 (-0.61%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$1.65 +0.01 (+0.61%) As of 07/7/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NERV vs. KLRS, BLUE, ADVM, VRCA, DTIL, AADI, ATRA, RNXT, VTVT, and APLTShould you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include Kalaris Therapeutics (KLRS), bluebird bio (BLUE), Adverum Biotechnologies (ADVM), Verrica Pharmaceuticals (VRCA), Precision BioSciences (DTIL), Aadi Bioscience (AADI), Atara Biotherapeutics (ATRA), RenovoRx (RNXT), vTv Therapeutics (VTVT), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry. Minerva Neurosciences vs. Its Competitors Kalaris Therapeutics bluebird bio Adverum Biotechnologies Verrica Pharmaceuticals Precision BioSciences Aadi Bioscience Atara Biotherapeutics RenovoRx vTv Therapeutics Applied Therapeutics Minerva Neurosciences (NASDAQ:NERV) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations. Is NERV or KLRS more profitable? Minerva Neurosciences' return on equity of -20.68% beat Kalaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A -20.68% 15.73% Kalaris Therapeutics N/A -62.08%-54.69% Do analysts recommend NERV or KLRS? Minerva Neurosciences presently has a consensus price target of $5.00, suggesting a potential upside of 204.88%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Kalaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer NERV or KLRS? In the previous week, Minerva Neurosciences had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 1 mentions for Minerva Neurosciences and 0 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.00 beat Minerva Neurosciences' score of -0.40 indicating that Kalaris Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Minerva Neurosciences Neutral Kalaris Therapeutics Neutral Which has better valuation & earnings, NERV or KLRS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A$1.44M$0.822.00Kalaris TherapeuticsN/AN/A-$58.77MN/AN/A Which has more volatility & risk, NERV or KLRS? Minerva Neurosciences has a beta of -0.34, suggesting that its share price is 134% less volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Do insiders & institutionals have more ownership in NERV or KLRS? 34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 8.6% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryMinerva Neurosciences beats Kalaris Therapeutics on 6 of the 10 factors compared between the two stocks. Get Minerva Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NERV vs. The Competition Export to ExcelMetricMinerva NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.54M$2.43B$5.52B$9.02BDividend YieldN/A1.78%5.24%4.08%P/E Ratio2.008.7527.1920.04Price / SalesN/A473.55395.22100.83Price / Cash7.9021.7726.2128.59Price / Book-0.454.497.925.55Net Income$1.44M$31.26M$3.17B$248.49M7 Day Performance-1.80%1.27%1.79%4.87%1 Month Performance-10.33%2.46%1.28%6.63%1 Year Performance-47.10%-0.29%33.32%20.38% Minerva Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NERVMinerva Neurosciences3.9232 of 5 stars$1.64-0.6%$5.00+204.9%-47.1%$11.54MN/A2.009Gap UpKLRSKalaris TherapeuticsN/A$2.67+1.9%N/AN/A$49MN/A0.00110Positive NewsGap UpBLUEbluebird bio2.0786 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520ADVMAdverum Biotechnologies4.0469 of 5 stars$2.15-7.3%$23.80+1,007.0%-67.6%$48.47M$1M-0.34190VRCAVerrica Pharmaceuticals3.6006 of 5 stars$0.53+1.4%$8.00+1,409.1%-89.1%$48.34M$7.57M-0.4440DTILPrecision BioSciences4.4876 of 5 stars$4.20-2.3%$47.00+1,019.0%-53.2%$47.68M$68.70M-2.09200AADIAadi Bioscience0.6347 of 5 stars$1.93+1.6%$1.67-13.6%+49.6%$47.67M$25.07M-0.8540ATRAAtara Biotherapeutics4.0778 of 5 stars$7.72-3.0%$17.75+129.9%+3.6%$47.45M$128.94M-2.08330Gap DownRNXTRenovoRx2.8749 of 5 stars$1.32+2.7%$7.25+451.3%+16.3%$46.81M$40K-3.296Positive NewsVTVTvTv Therapeutics1.9501 of 5 stars$15.00+3.5%$35.50+136.7%-14.1%$46.29M$1.02M-4.989APLTApplied Therapeutics3.7598 of 5 stars$0.31-3.9%$6.10+1,860.8%-92.6%$45.84M$460K-0.7230Gap Up Related Companies and Tools Related Companies Kalaris Therapeutics Alternatives bluebird bio Alternatives Adverum Biotechnologies Alternatives Verrica Pharmaceuticals Alternatives Precision BioSciences Alternatives Aadi Bioscience Alternatives Atara Biotherapeutics Alternatives RenovoRx Alternatives vTv Therapeutics Alternatives Applied Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NERV) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
